|
|
||||||||
Stem Cells, Vol 11, 283-289, Copyright © 1993 by AlphaMed Press
REVIEWS |
LB To
Leukaemia Research Unit, Hanson Centre for Cancer Research, Adelaide, Australia.
Autologous hemopoietic stem cell rescue following high-dose chemoradiotherapy is increasingly used in the treatment of lymphohemopoietic malignancy and selected solid tumors. While encouraging disease control has been reported in acute leukemia, lymphoma, multiple myeloma and breast carcinoma, such an approach suffers from a number of limitations. This review addresses a number of issues that may lead to better stem cells for transplant: which stem cell rescue provides the most rapid hemopoietic reconstitution, how can we get sufficient high quality stem cells for transplant to ensure complete and sustained reconstitution, what are the predictors of rapid and sustained hemopoietic reconstitution, what impact on hemopoietic reconstitution purging and positive selection technology may have, and how can we abrogate the obligatory delay to blood count recovery.
This article has been cited by other articles:
![]() |
L.B. To, D.N. Haylock, P.J. Simmons, and C.A. Juttner The Biology and Clinical Uses of Blood Stem Cells Blood, April 1, 1997; 89(7): 2233 - 2258. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
